cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Company profile
Ticker
CARA
Exchange
Website
CEO
Derek Chalmers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cara Therapeutics Inc
SEC CIK
Corporate docs
Subsidiaries
Cara Royalty Sub, LLC ...
CARA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
22 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
22 Jan 24
Transcripts
CARA
Earnings call transcript
2023 Q4
4 Mar 24
CARA
Earnings call transcript
2023 Q3
13 Nov 23
CARA
Earnings call transcript
2023 Q2
7 Aug 23
CARA
Earnings call transcript
2023 Q1
15 May 23
CARA
Earnings call transcript
2022 Q4
6 Mar 23
CARA
Earnings call transcript
2022 Q3
8 Nov 22
CARA
Earnings call transcript
2022 Q2
9 Aug 22
CARA
Earnings call transcript
2022 Q1
9 May 22
CARA
Earnings call transcript
2021 Q4
2 Mar 22
CARA
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Joana Goncalves
9 Apr 24
4
Scott Terrillion
9 Apr 24
4
Scott Terrillion
4 Mar 24
4
Christopher Posner
4 Mar 24
4
Joana Goncalves
4 Mar 24
SC 13G/A
Bain Capital Life Sciences Opportunities III, LP
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Scott Terrillion
12 Feb 24
4
Ryan D Maynard
12 Feb 24
4
Joana Goncalves
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.78 mm | 64.78 mm | 64.78 mm | 64.78 mm | 64.78 mm | 64.78 mm |
Cash burn (monthly) | (no burn) | (no burn) | 9.63 mm | 10.02 mm | 6.55 mm | 8.18 mm |
Cash used (since last report) | n/a | n/a | 65.44 mm | 68.05 mm | 44.49 mm | 55.61 mm |
Cash remaining | n/a | n/a | -661.63 k | -3.27 mm | 20.29 mm | 9.17 mm |
Runway (months of cash) | n/a | n/a | -0.1 | -0.3 | 3.1 | 1.1 |
Institutional ownership, Q3 2023
68.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 17 |
Closed positions | 33 |
Increased positions | 34 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 44.41 bn |
Total shares | 37.22 mm |
Total puts | 16.00 k |
Total calls | 63.70 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vifor | 7.40 mm | $0.00 |
BLK Blackrock | 3.71 mm | $6.23 bn |
Bain Capital Life Sciences Opportunities III | 2.70 mm | $25.61 mm |
Vanguard | 2.60 mm | $4.37 bn |
Disciplined Growth Investors | 1.77 mm | $2.98 bn |
Chescapmanager | 1.76 mm | $2.95 bn |
Farallon Capital Management | 1.67 mm | $2.80 bn |
Jacobs Levy Equity Management | 1.44 mm | $2.43 bn |
Geode Capital Management | 972.86 k | $1.63 bn |
Clearbridge Advisors | 971.61 k | $1.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Terrillion Scott | Common Stock | Sell | Dispose S | No | Yes | 0.83 | 2,753 | 2.28 k | 88,247 |
5 Apr 24 | Goncalves Joana | Common Stock | Sell | Dispose S | No | Yes | 0.83 | 2,753 | 2.28 k | 53,365 |
29 Feb 24 | Goncalves Joana | Common Stock | Sell | Dispose S | No | Yes | 0.89 | 3,293 | 2.93 k | 56,118 |
29 Feb 24 | Posner Christopher | Common Stock | Sell | Dispose S | No | Yes | 0.89 | 5,834 | 5.19 k | 180,521 |
29 Feb 24 | Terrillion Scott | Common Stock | Sell | Dispose S | No | Yes | 0.89 | 3,293 | 2.93 k | 91,000 |
News
Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 18, 2024
18 Apr 24
Bearish Monday For Marijuana Stocks - AusCann Group Holdings, Target Group Among Top Gainers
15 Apr 24
Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
10 Apr 24
Marijuana Stock Movers For April 8, 2024
8 Apr 24
Bullish Sentiment Across The Cannabis Space - Check Full Movers For April 5, 2024
5 Apr 24
Press releases
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
7 Mar 24
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
4 Mar 24
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
12 Feb 24